All In Biotech

Drug Trial Radar · NCT06369298

Study of JK07 in Patients With Chronic Heart Failure

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of JK07 in Adults With Chronic Heart Failure (RENEU-HF)

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 282 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

282

Planned (sponsor's estimate)

Start

Mar 28, 2024

Primary completion

Oct 31, 2026

Study completion Oct 31, 2026

Sponsor

Lead sponsor
Salubris Biotherapeutics IncIndustry
Sponsor type
Industry
First posted
Apr 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.

Conditions

  • Heart Failure With Reduced Ejection Fraction
  • Heart Failure With Preserved Ejection Fraction

Interventions

  • JK07Drug

    JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.

  • PlaceboDrug

    0.9% sodium chloride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Cohort 1Time frame: Study entry through week 52
  2. Efficacy - Cohort 1Time frame: Baseline through week 26
  3. Safety - Cohort 2Time frame: Study entry through week 52

Locations

62 sites in 4 countries. Site status is shown where the registry gives one.

  • Site 121

    Alexander City, Alabama

  • Site 130

    Birmingham, Alabama

  • Site 139

    Birmingham, Alabama

  • Site 138

    Huntsville, Alabama

  • Site 111

    Phoenix, Arizona

  • Site 127

    Little Rock, Arkansas

  • Site 128

    Huntington Beach, California

  • Site 157

    Los Angeles, California

  • Site 158

    Orange, California

  • Site 116

    Pasadena, California

  • Site 129

    Santa Maria, California

  • Site 102

    Stanford, California

  • Site 113

    Torrance, California

  • Site 133

    Vista, California

  • Site 161

    Coral Gables, Florida

  • Site 114

    Hialeah, Florida

  • Site 162

    Miami Lakes, Florida

  • Site 159

    Naples, Florida

  • Site 136

    Atlanta, Georgia

  • Site 143

    Boise, Idaho

  • Site 160

    Chicago, Illinois

  • Site 154

    Park Ridge, Illinois

  • Site 137

    Fort Wayne, Indiana

  • Site 112

    Indianapolis, Indiana

  • Site 104

    Covington, Louisiana

  • Site 118

    Baltimore, Maryland

  • Site 119

    Boston, Massachusetts

  • Site 122

    Bloomfield Hills, Michigan

  • Site 150

    Farmington Hills, Michigan

  • Site 107

    Rochester, Minnesota

  • Site 106

    St Louis, Missouri

  • Site 105

    St Louis, Missouri

  • Site 144

    Brick, New Jersey

  • Site 153

    Valhalla, New York

  • Site 152

    Asheville, North Carolina

  • Site 109

    Cary, North Carolina

  • Site 140

    Charlotte, North Carolina

  • Site 145

    Durham, North Carolina

  • Site 117

    Cincinnati, Ohio

  • Site 100

    Cleveland, Ohio

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.